Secreted Frizzled-related proteins (sFRPs) have emerged as key regulators of a wide range of developmental and disease processes. Most of the known functions of mammalian sFRPs have been attributed to their ability to antagonize Wnt signalling. Recently however, Xenopus laevis and zebrafish sFRP, Sizzled, was shown to function as an antagonist of Chordin processing by Tolloid-like metalloproteinases. This has led to the proposal that sFRPs may function as evolutionarily conserved antagonists of chordinase activities of this class of proteinases. In contrast to this proposal, we show here that the mammalian sFRP, sFRP2, does not affect Chordin processing, but instead, can serve as a direct enhancer of procollagen C proteinase activity of Tolloidlike metalloproteinases. We also show that the level of fibrosis, in which procollagen processing by Tolloid-like proteinases has a rate-limiting role, is markedly reduced in Sfrp2-null mice subjected to myocardial infarction. Importantly, this reduced level of fibrosis is accompanied by significantly improved cardiac function. This study thus uncovers a function for sFRP2 and a potential therapeutic application for sFRP2 antagonism in controlling fibrosis in the infarcted heart. Secreted Frizzled-related proteins (sFRPs) are a family of proteins that share a cysteine-rich (CR) domain with the extracellular region of the Frizzled (Fzl) Wnt receptors [1] [2][3][4][5] . sFRPs bind Wnt molecules through this CR-domain and inhibit Wnt-mediated signal transduction [1] [2][3][4][5] . In mice and humans, five family members, sFRP1-5, have been identified and have recently emerged as regulators of a wide range of developmental and disease processes [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . All such functions of sFRPs in mice and humans have been attributed to antagonism of Wnt signalling.
Secreted Frizzled-related proteins (sFRPs) are a family of proteins that share a cysteine-rich (CR) domain with the extracellular region of the Frizzled (Fzl) Wnt receptors [1] [2] [3] [4] [5] . sFRPs bind Wnt molecules through this CR-domain and inhibit Wnt-mediated signal transduction [1] [2] [3] [4] [5] . In mice and humans, five family members, sFRP1-5, have been identified and have recently emerged as regulators of a wide range of developmental and disease processes [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . All such functions of sFRPs in mice and humans have been attributed to antagonism of Wnt signalling.
However, two studies have proposed that sFRPs have other function besides their effects on Wnt signalling 23, 24 . In zebrafish, Xenopus and Drosophila melanogaster, dorsal-ventral patterning during gastrulation is established by cross-talk between ventral and dorsal centres that spatially and temporally regulates bone morphogenetic protein (BMP) activity gradient 25, 26 . In vertebrates, the dorsal centre secretes BMP antagonists, including Chordin, whereas the ventral centre expresses Tolloid (TLD) family metalloproteinases and the sFRP family member, Sizzled (Szl). A gradient of BMP activity is set by Chordin, which is in turn inactivated through cleavage by TLD-like proteinases. In recent studies of Xenopus and zebrafish dorsal-ventral patterning, Szl was shown to bind TLD-like proteinases, thereby inhibiting Chordin cleavage 23, 24 . Thus, Szl seems to regulate BMP signalling and dorsal-ventral patterning during embryo gastrulation, through its activity as a competitive inhibitor of TLD-like proteinases.
In mammals, there are four TLD-like proteinases: BMP1, mTLD, mTLL1 and mTLL2 (ref. 27 ). BMP1 and mTLL1, but not mTLD or mTLL2, are responsible for cleaving Chordin, whereas all four can exhibit some level of procollagen C proteinase (pCP) activity, which converts procollagen precursors into the major fibrillar components of the extracellular matrix (ECM), with BMP1 showing highest pCP activity 27 . In fact, the mammalian TLD-like proteinases biosynthetically process a variety of precursors into mature functional proteins involved in ECM formation, and also have roles in activating TGFβ superfamily members myostatin/GDF-8, GDF11, and TGFβ 27, 28 . Although it has been shown that Szl functions as a competitive inhibitor of TLD-like proteinase cleavage of Chordin in Xenopus and zebrafish, it has not been clear whether this function of sFRP proteins is conserved in mammals. It has been reported that Szl inhibits Xenopus BMP1 cleavage of a synthetic peptide substrate that resembles a procollagen C-propeptide cleavage site, and that mouse sFRP2 can inhibit Xenopus Chordin cleavage by the Xenopus TLD-like proteinase Xlr 23 .
A R T I C L E S
However, the question of whether mammalian sFRPs, such as sFRP2, actually inhibit cleavage of mammalian physiological substrates by TLDlike proteinases has yet to be explored.
Here we show that sFRP2 does not inhibit cleavage of mammalian Chordin by mammalian BMP1 or mTLL1. Thus, inhibition of Chordin cleavage is not a general property of sFRPs. Rather, sFRP2 is shown to enhance the pCP activity of mammalian BMP1 in vitro, consistent with significantly reduced levels of procollagen processing and collagen deposition in Sfrp2-null fibroblast cultures and of fibrosis in Sfrp-null mice subjected to myocardial infarction, as demonstrated here. Thus, our study reveals a function of sFRP as an enhancer of pCP activity of TLD-like metalloproteinases in mammals. Furthermore, it suggests the possibility of using sFRP2 antagonists in controlling fibrosis in the infarcted heart.
RESULTS:
sFRP2, but not Szl, is an enhancer of BMP1 pCP activity Recent studies in Xenopus and zebrafish led to the proposal that sFRPs function as evolutionarily conserved competitive inhibitors of the TLDlike proteinases, with a particularly important role in inhibiting the chordinase activity of these proteinases in development 23, 24 . However, in these studies, the ability of mammalian sFRP2 to inhibit cleavage of mammalian Chordin by mammalian TLD-like proteinase was not shown. Therefore, we re-evaluated this notion by studying the effects of sFRP2, a mammalian sFRP, on the processing of various physiological substrates of mammalian TLD-like proteinases. Surprisingly, despite reports that murine sFRP2 inhibits cleavage of Xenopus Chordin by the Xenopus TLD-like proteinase, Xlr 23 , no obvious differences in the extent of cleavage of murine Chordin by BMP1 or mTLL1 occurred in the Immunoblots show that increasing concentrations of sFRP2 have no effect on the cleavage of Chordin by BMP1 (a) or mTLL1 (b), whereas Szl efficiently inhibits Chordin cleavage by BMP1 (c), with a much reduced inhibitory effect on Chordin cleavage shown by Szl with an ogonlike D92N mutation (d). Chordin cleavage is indicated by the appearance of an N-terminal fragment with a relative molecular mass of 15,000 (M r 15K, arrow). (e, f) In contrast to the absence of sFRP2 effects on Chordin cleavage, autofluorography shows that a 2-fold molar excess of sFRP2 enhanced BMP1 pCP activity, such that no unprocessed pro-forms of the two chain classes of type I procollagen (proα1 and proα2) remained, and greater amounts of pN forms (processing intermediates retaining N-propeptides, but from which C-propeptides have been cleaved) for both chain classes were produced, compared with processing with BMP1 alone (e). Szl inhibits, and Szl
D92N
has no apparent effect, on BMP1 pCP activity (f). Fold-enhancement of pro-α1(I) to pNα1(I) chain processing by sFRP2 ranged from 1.2-to 2.0-fold in six independent experiments (1.4-fold in e) and in the four of these experiments in which pro-α2(I) to pNα2(I) chain ratios could be compared, fold-enhancement of pro-α2(I) processing ranged from 1.2-to 2.6-fold (such a comparison could not be made in e, in which no uncleaved proα2(I) chains remained after cleavage of procollagen by BMP1 in the presence or absence of sFRP2). presence or absence of sFRP2 (Fig. 1a, b) . In contrast, Szl was efficient in inhibiting cleavage of mammalian Chordin by mammalian BMP1 (Fig. 1c ), but Szl with the ogon mutation (Szl D92N ) showed much less efficient inhibition (Fig. 1d) , essentially as reported for Szl and Szl D92N in studies of the inhibition of Xenopus 23 and zebrafish 24 Chordin cleavage by TLD-like proteinases.
Due to the lack of sFRP2 effects on chordinase activity of mammalian TLD-like proteinases, we next assayed for possible effects of mouse sFRP2 on the cleavage of other substrates by TLD-like proteinases. In the course of testing several known substrates for this metalloproteinase family, we found that not only did sFRP2 not have the predicted 23 ability to inhibit BMP1 pCP activity, but that it actually enhanced this activity (Fig. 1e) . In contrast, as with Chordin, zebrafish Szl was found to inhibit pCP activity (Fig. 1f) , and this inhibitory activity was similarly suppressed in the Szl D92N mutant. These results are consistent with the notion that the non-mammalian sFRP, Szl, inhibits both chordinase and pCP activities of TLD-like proteinases, whereas the mammalian sFRP, sFRP2, enhances pCP activity, but is ineffective in modulating chordinase activity. sFRP2 binds BMP1 through its frizzled domain with affinity in the physiological range To gain insight into the mechanism by which sFRP2 enhances BMP1 pCP activity, we tested whether sFRP2, like Szl 23, 24 , is capable of binding this class of proteinases. sFRP2 was found to bind BMP1 in pulldown experiments (Fig. 2a) , confirming interaction of the two proteins. Surface plasmon resonance (BIAcore) analysis showed the sFRP2-BMP1 interaction occurred with an affinity (K D = 7.13 nM; Fig. 2b ) in the range in which proteins at physiological concentrations are likely to interact, a slightly higher affinity than that previously estimated for the binding of Szl to non-mammalian TLD-like proteinases 23 . We next determined the sFRP2 protein domain that mediates this interaction. There are two major protein domains in sFRP2: a cysteinerich Fzl domain and a netrin (NTR) domain (Fig. 2e ) [1] [2] [3] 29, 30 . A pulldown assay clearly showed that the sFRP2 Fzl domain is sufficient for binding BMP1, whereas little binding was observed for the NTR domain (Fig. 2c) . Consistent with the pulldown results, BIAcore analysis showed that affinity of Fc-tagged sFRP2 Fzl-domain for BMP1 (K D ~8.68 nM) was in the same physiological range as that of full-length Fc-tagged sFRP2 (K D ~ 6.01 nM), whereas NTR-domain binding to BMP1 was negligible (Fig. 2d) .
These results demonstrate a direct and specific interaction of sFRP2 with BMP1, with affinity in the physiological range, suggesting that sFRP2 enhances BMP1 pCP activity by directly interacting with BMP1 through its Fzl-domain.
sFRP2 and Szl bind TLD-like proteinases through non-protease domain sequences
To determine how sFRP2 binding to BMP1 enhances pCP activity of the latter, we evaluated whether sFRP2 directly binds the BMP1 protease domain, which contains the active site. Pulldown assays showed that sFRP2 fails to bind the BMP1 protease domain (BMP1-P), but instead, strongly binds a deleted version of BMP1 lacking the protease domain (BMP1-D; Fig. 3a, e) . Similarly, sFRP2 failed to bind the protease domain of another TLD-like proteinase, mTLL1 (mTLL1-P) (Fig. 3b, e) . Surprisingly, the same specific mode of interaction was found for Szl, which similarly bound the non-protease domain portions of the TLD-like proteinases (Fig. 3c-e) , although it has been proposed that Szl was likely to act on the active sites of TLD-like proteinases 23 . Our results suggest that interaction of sFRP2 with the non-protease domain portions of BMP1 and mTLL1 induces conformational changes of these proteinases, resulting in enhanced pCP but not chordinase Time (s)
BMP1: activity of these enzymes. In contrast, binding of Szl results in suppression of both pCP and chordinase activities of the enzymes.
The interaction of BMP1 proteinase and its substrate, procollagen, is enhanced by sFRP2
We next examined whether sFRP2 might influence the actual binding of procollagen to TLD-like proteinases, in a pulldown assay using a form of BMP1 designed to bind but not cleave or release substrates 31 . Immunoprecipitation of procollagen also pulled down sFRP2, demonstrating that sFRP2 binds procollagen (Fig. 3f) . Moreover, co-immunoprecipitation of procollagen and BMP1 was greatly enhanced in the presence of sFRP2 (that is, the ratio of signal for co-precipitated BMP1 to signal for immunoprecipitated pro-α1(I) chains was about 4-fold stronger in the presence than in the absence of sFRP2), indicating that sFRP2 enhances BMP1/procollagen binding (Fig. 3f) . These results also suggest that sFRP2 enhancement of pCP activity may involve formation of a tripartite complex consisting of sFRP2, BMP1 and procollagen. procollagen processing in cultures of wild-type and Sfrp2-null fibroblasts. Sfrp2-null mice were generated by inserting lacZ into the first exon of the Sfrp2 gene ( Supplementary Information, Fig. S1 ) and fibroblasts were isolated from embryos (MEFs) and from adult heart. Both MEFs and heart fibroblasts isolated from wild-type mice expressed endogenous sFRP2, whereas sFRP2 expression was, as expected, not detected in Sfrp2-null fibroblasts ( Supplementary Information, Fig. S2 ). In conditioned medium of wild-type MEF and heart fibroblasts, about 63% and 73% of type I procollagen precursor, respectively, was processed to mature collagen ( Fig. 4a-d ). In contrast, only 19% and 42% of the precursor was processed to mature collagen in conditioned medium from Sfrp2-null MEFs and heart fibroblasts, respectively ( Fig. 4a-d) . Furthermore, as procollagen C-propeptide cleavage seems to be the rate-limiting step in collagen fibrillogenesis 27 , it is notable that wild-type MEFs were found to deposit 2.5-fold more mature collagen into cell layer-associated ECM than did Sfrp2-null MEFs, whereas wild-type heart fibroblasts deposited 11-fold more collagen into ECM than did their Sfrp2-null counterparts (Fig. 4a, b, e, f) . These marked reductions in procollagen processing and in the deposition of collagen into ECM thus support the biochemical data, indicating that sFRP2 is an enhancer of the pCP activity of TLD-like proteinases.
sFRP2 expression is upregulated in the fibrotic phase of myocardial infarction Procollagen processing by TLD-like proteinases is an important rate-limiting step in collagen fibrillogenesis, and thus in the pathological process of fibrosis 27 , which occurs in many fatal disease conditions, including myocardial infarction, the leading cause of death in men and women 32, 33 . We therefore examined sFRP2 expression in a mouse myocardial infarction model (Fig. 5a, b) . Following coronary artery ligation, insufficient oxygen supply leads to damage and death of cardiomyocytes due to apoptosis and necrosis 32, 33 . sFRP2 expression was not detected during this initial phase (Fig. 5a ). This first phase is followed by fibrosis, in which dead myocytes are removed and replaced by collagenous ECM that forms the fibrotic scar tissue. We detected 20-to 30-fold upregulation of Sfrp2 RNA transcript levels 4 days after coronary artery ligation (Fig. 5b) , coinciding with appearance of extraneous Sirius-red-positive collagen fibres, indicating the beginning of fibrosis (Fig. 5a ). The sFRP2-expressing cells have a fibroblastic appearance and scattered distribution. By day 7, we detected about 80-to 100-fold upregulation of Sfrp2 transcript levels (Fig. 5b) , and the Sirius-red-positive fibrotic area had expanded, replacing dead myocytes (Fig. 5a ). The sFRP2-expressing fibroblastic cells were distributed widely throughout the fibrotic area. At day 14 following ligation, the Sfrp2 transcript level was somewhat reduced, but an increase of about 30-to 40-fold was still detected (Fig. 5b) . Upregulation of BMP1 expression followed the same temporal expression pattern as that of sFRP2 in infarcted heart (Fig. 5b) , whereas mTLL1, another TLD-like proteinase capable of procollagen processing, showed little expression in infarcted hearts (Fig. 5b) . Temporal correspondence of sFRP2 and BMP1 expression patterns, together with the specific expression of sFRP2 in fibroblastic cells in fibrotic areas, is consistent with the conclusion that sFRP2 enhancement of BMP1-mediated procollagen processing has an important role in the fibrotic component of myocardial infarction.
Reduced fibrosis and improved cardiac function of the infarcted

Sfrp2-null heart
We next examined the extent of fibrosis in the Sfrp2-null heart after coronary artery ligation (Fig. 6) . Age-matched Sfrp2-null and wildtype mice were subjected to this surgical procedure and areas of fibrosis in the left ventricle were measured by staining collagen fibres with Sirius red. By day 14 after coronary artery ligation, about 25-35% of the wild-type left ventricle was stained with Sirius red, indicating severe -/-heart fibroblasts, samples were re-probed with anti-α-tubulin antibody to demonstrate equal loading in the two lanes. Densitometric quantification is shown of the relative amounts of the various collagen forms in conditioned media of MEFs (c) and heart fibroblasts (d). Pro-forms are precursors that retain both N-and C-propeptides; α1(I) forms are mature chains, capable of forming fibrils, from which both N-and C-propeptides have been proteolytically removed; pN forms are processing intermediates of proα1(I) chains from which the C-but not N-propeptide has been removed by BMP1-like proteinases; pC forms are processing intermediates from which the Nbut not C-propeptide has been removed by non-BMP1-like proteinases. pC and pN forms were not separated by SDS-PAGE in these experiments. (e, f) Densitometric quantification is shown of the relative amounts of mature α1(I) chains incorporated into cell layer-associated ECM of wild-type (+/+) and Sfrp-null (-/-) MEFs (e) and heart fibroblasts (f). For full scans of a and b, see Supplementary Information, Fig. S6 . fibrosis (Fig. 6a, b) . In contrast, only about 15-20% of the left ventricle of Sfrp2-null heart was stained (Fig. 6a, b) . As an independent readout of fibrosis, we measured the amount of hydroxyproline, which reflects the total amount of mature, fully processed collagen deposited into tissue fibrils 34, 35 . In sham-operated control wild-type and Sfrp2-null hearts, about 2-5 μg hydroxyproline was present per mg dry weight of the left ventricle (Fig. 6c) . In the infarcted wild-type heart, about 10-16 μg hydroxyproline was detected per mg dry weight left ventricle (Fig. 6c) . In contrast, only 3-8 μg hyroxyproline per dry weight left ventricle was detected in Sfrp2-null heart (Fig. 6c) . This reduced fibrosis and mature collagen content of infarcted Sfrp2-null hearts is consistent with the role of sFRP2 in enhancing BMP1 procollagen processing, and thus collagen deposition, indicated by biochemical and cell culture studies (Figs 1, 4) .
The functional consequence of reduced fibrosis in Sfrp2-null hearts was studied by cardiac echocardiography monitoring in both wild-type and Sfrp2-null mice after coronary artery ligation. At day 7 after coronary artery ligation, both Sfrp2-null and wild-type control hearts showed a wide range of ejection fraction (EF) and no significant differences were detected between them (Fig. 7a, c) . By day 14 following ligation, wild-type heart EFs dropped consistently to 10-20%, markedly lower than EFs of sham-operated control hearts (Fig. 7b-d) . In contrast, EFs of Sfrp2-null hearts remained in the 25-65% range, with some of them even staying at 60-65%, a range essentially indistinguishable from that of sham-operated controls (Fig. 7b-d) . Time-lapse cinematography revealed relatively active hearts beating in the infarcted Sfrp2-null mice ( Supplementary Information, Movie 2) . In contrast, infarcted wild-type hearts showed very little beating, due to severe dilation of the ventricular wall resulting from extensive myocardial cell death and fibrosis ( Supplementary Information, Movie 1) . DISCUSSION sFRPs have long been considered endogenous antagonists of Wnt signalling 36 . However, recent studies in Xenopus and zebrafish have questioned this notion and shown that at least one sFRP, Szl, functions as a competitive inhibitor of Chordin cleavage by directly binding TLD-like proteinases 23, 24 . This non-Wnt signalling function of Szl seems to have a key role in dorsal-ventral patterning of early embryos 23, 24 . Furthermore, it was reported that mammalian sFRP2 can inhibit Xenopus Chordin cleavage by the Xenopus TLD-like proteinase, Xlr 23 . On the basis of this result, it was proposed that the ability to block chordinase activity of TLD-like proteinases is shared by all sFRPs and is evolutionarily conserved 23 .
Here, we present biochemical evidence that mammalian sFRP2 does not act as an inhibitor of the chordinase activity of mammalian TLD-like proteinases BMP1 and mTLL1 (Fig. 1a, b) , but that instead, it functions as an enhancer of the pCP activity of such proteinases (Fig. 1e) . The conclusion that sFRP2 is a physiological enhancer of procollagen processing is further substantiated by the marked reduction of type I procollagen processing by Sfrp2-null fibroblasts (Fig. 4) and of fibrosis in infarcted Sfrp2-null hearts (Fig. 6) .
What is the mechanism underlying this pCP enhancer function of sFRP2? In previous studies 23, 24 , it was shown that Szl directly binds TLD-like proteinases through its Fzl domain, thus mediating the inhibition of chordinase activity. In one of the studies 23 , it was further proposed that Szl inhibits chordinase activity by acting directly on the active site within the protease domain of TLD-like proteinases. This proposal was primarily based on competitive enzyme kinetics assays 23 , but direct interaction of Szl with the protease domains of TLD-like proteinases was not demonstrated.
In our present studies we show that sFRP2, like Szl, has specific and physiological interactions with both BMP1 and mTLL1 through its Fzl domain (Fig. 2) . However, contrary to the previous proposal, our study shows that neither Szl nor sFRP2 bind the protease domain of BMP1 or mTLL1, but instead bind the non-protease portions of these two proteinases (Fig. 3) . On the basis of these results, we propose an alternative mechanism: Szl and sFRP2 exert their differing effects on TLD-like proteinases through binding domains other than the active site containing the protease domain. Szl probably inhibits chordinase left-ventricle at 1, 4, 7 and 14 days after coronary artery ligation. Higher magnifications of the boxed areas in the top panels are shown in the bottom panels. At day 1, the Sirius red counterstaining (orange) identifies normal collagen in the interstitial space. At this stage, no sFRP2 expression was detected. At day 4, the slightly wider areas are stained with Sirius red (orange), which is accompanied by scattered distribution of β-galactosidase-stained sFRP2-expressing fibroblastic cells (blue). By day 7, extensive collagenous fibrosis stained with Sirius red (orange) was detected. Within the fibrotic area, many fibroblastic cells express sFRP2 (blue). At day 14, more extensive Sirius red staining, denoting collagenous scar tissue that has replaced dead myocytes, was clearly detected, and many fibroblastic cells were seen to express sFRP2 (blue). Upregulation of sFRP2 expression in the infarcted area was also confirmed by in situ hybridization staining with a riboprobe for sFRP2 ( Supplementary Information, Fig. S3 activity by competing with Chordin for binding to non-protease domain sites of TLD-like proteinases, or perhaps such binding by Szl induces conformational changes in the proteinases that preclude Chordin binding. Similarly, sFRP2 binding to non-protease domain sites probably enhances pCP activity by facilitating the interaction between procollagen substrates and TLD-like proteinases, which seems to involve formation of a tripartite complex comprising sFRP2, proteinase and procollagen substrate (Fig. 3f) . Interestingly, this latter mechanism of pCP enhancement by sFRP2 is similar to that of the other family of pCP enhancers, PCOLCEs/PCPEs, which have been shown to enhance pCP activity by binding both procollagen substrates and the non-protease domains of TLD-like proteinases [37] [38] [39] [40] . Similarly, the mechanism involving Szl inhibition of chordinase activity through interactions with nonprotease domain sequences is consistent with the previous finding that the chordinase activity of a given TLD-like proteinase can in large part be determined by its non-protease protein domains 41 . Genetic studies of zebrafish identified the ogon mutant in which a missense Asp>Asn mutation in the Szl Fzl domain at position 92 (D92N) results in production of functionally null Szl protein 42, 43 . In previous studies 23, 24 , functional significance of Fzl-domain-mediated interaction of Szl with TLD-like proteinases was further suggested by showing that the D92N ogon-mutation in the Fzl domain abrogates inhibition of chordinase activity by Szl in vitro and in vivo 23 . However, a seemingly corresponding mutation of Asp 105 to Asn (D105N) in the Fzl domain of mammalian sFRP2 had no effects on pCP enhancer activity (data not shown).
Excessive collagen fibre formation results in fibrosis in various life-threatening human diseases. Removal of procollagen C-terminal propeptides by TLD-like proteinases is a crucial and rate-limiting biochemical step in this process 27 . Myocardial infarction is one disease in which fibrosis reflects the severity of the prognosis. Our study shows significant co-induction of sFRP2 and BMP1 expression during fibrosis ( Fig. 5; Supplementary Information, Figs S3, S4 ) and, importantly, markedly reduced fibrosis (Fig. 6 ) in the infarcted Sfrp2-null heart. These in vivo results are consistent with our biochemical results indicating that sFRP2 is an enhancer of BMP1 pCP activity (Figs 1, 4) . On the basis of these results, we propose that co-induction of BMP1 and sFRP2, shown here to occur during fibrosis, and the consequently enhanced procollagen processing, are key drivers of the formation and deposition of the extensive collagen fibrils that constitute severe fibrosis.
The possibility that sFRP2 might function as an autocrine factor to either enhance proliferation or suppress death of sFPR2-expressing fibroblastic cells, seems to be excluded. In this model, the total number of sFRP2-expressing fibroblastic cells would be reduced in infarcted Sfrp2-null heart, thereby reducing the extent of fibrosis, as collagen is deposited by these fibroblastic cells 44, 45 . Analysis of the number of formerly sFRP2-expressing fibroblastic cells after coronary artery ligation did not, however, provide evidence for such a reduction of fibroblastic cells ( Supplementary  Information, Fig. S5.) , arguing against a role for sFRP2 as a proliferative or survival factor for cardiac fibroblastic cells involved in fibrosis.
Cardiac fibrosis is known to have adverse effects on left ventricular function [44] [45] [46] , thus forming a therapeutic basis for the use of anti-fibrotic agents to inhibit or reverse such adverse effects [44] [45] [46] . Our study shows that reduced fibrosis in the infarcted Sfrp2-null heart is accompanied by markedly improved performance, compared with the infarcted wild-type heart (Fig. 7) , suggesting that antagonism of sFRP2 may prove to be an effective therapeutic approach to controlling fibrosis and improving cardiac function in myocardial infarction, which accounts for about 13% of deaths worldwide and is the leading cause of death in developed countries.
In summary, we provide in vitro and in vivo evidence supporting the concept of sFRP2 as an endogenous enhancer of procollagen C-proteinase activity. Our findings indicate that urgent re-evaluation of previously reported roles for sFRPs in various processes presumed to be dependent on the inhibition of Wnt signalling is required. Furthermore, our biochemical studies suggest that pCP enhancement mediated by formation of a tripartite complex consisting of a TLD-like proteinase, a procollagen (that is, substrate) and a pCP enhancer may be a common mechanism underlying the function of two distinct classes of pCP enhancers, sFRP2 and PCOLCEs/PCPEs.
METHODS
Biochemical and cell biology methods. Recombinant murine Chordin, and human BMP1 and mTLL1 were prepared, and cleavage assays performed as described previously 47 . Mutant BMP1 (BMP1*) designed to bind but not cleave or release substrates, due to an E214A substitution at the active site, has been described previously 31 , as has a FLAG-tagged BMP1 consisting only of pro-and protease domains 40 . FLAG-tagged BMP1 lacking the protease domain, and C-terminal His-tagged Xenopus wild-type Szl and Szl D92N were prepared as detailed in the Supplementary Information. For Chordin cleavage, 15 ng BMP1 or mTLL1 was incubated with Chordin (100 ng) for 16 h at 37 °C with or without mouse sFRP2 (R&D Systems), Szl, or Szl D92N , in amounts noted in the figure, in 50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl 2 (buffer A). After SDS-PAGE on 10% acrylamide gels, western blotting was performed with a previously described anti-Chordin N terminus antibody 48 . For procollagen processing, 400 ng 3 H-labelled type I procollagen, prepared as described previously 47 , was incubated in buffer A with 15 ng BMP1 at 37 °C with or without 20 nM sFRP2 or 40 nM Szl or Szl D92N . sFRP2 (20 nM) or Szl or Szl D92N (40 nM), in the absence of proteinase, were used as controls. Reactions were stopped after 16 h at 37 °C by adding SDS sample buffer. Proteins were separated on 5% SDS-PAGE gels, followed by treatment with EN 3 HANCE (PerkinElmer) and autofluorography. Various immunoprecipitations and co-immunoprecipitations are described in detail in the Supplementary Information.
Surface plasmon resonance measurements were performed in a BIAcore 2000 system, as described in detail in Supplementary Information.
To compare collagen processing and deposition in cell-associated matrix, wildtype and Sfrp2-null fibroblasts were cultured in DMEM containing 10% FBS, and treated for 24 h with 50 μg ml -1 ascorbate. Cells were washed twice with PBS, and incubated for 15 min in serum-free DMEM at 37 °C. Cells were then washed once with PBS, followed by addition of serum-free DMEM containing 50 μg ml -1 ascorbate and 40 μg ml -1 soybean trypsin inhibitor. Conditioned medium was collected after 24 h. Cell layers were washed twice with ice-cold PBS and scraped into hot SDS-sample buffer. Western blotting was performed with anti-α1(I) C-telopeptide polyclonal antibody LF67, as described previously 49 . Blots were scanned and quantified with Image J 1.36b software. lacZ/lacZ hearts at day 14 following coronary artery ligation. The WT heart showed virtually no pumping. In contrast, the Sfrp2 lacZ/lacZ heart showed some pumping activity. The time-lapse movie of each heart can be viewed in Supplementary Information, Movies 1, 2.
Generation of
Quantitative RT-PCR (qRT-PCR).
Total RNA was isolated by RNeasy Midi kit (Qiagen) according to the manufacturer's protocol. For RNA isolation from heart tissues, the homogenate was passed through a cell strainer (100 μm) to prevent clogging of the column. cDNA was synthesized using the SuperScript first-strand synthesis system (Invitrogen). qRT-PCR was performed using the QuantiTect SYBR Green PCR kit (Qiagen) and M×4000 multiplex Quantitative PCR system (Stratagene). The primer sequences are available in the Supplementary Information.
GAPDH qRT-PCR was used as an internal control and to normalize each genespecific qRT-PCR. The absolute amounts of Sfrp2 transcripts were determined using a standard curve of known amounts of Sfrp2 cDNA in the quantitative RT-PCR reactions.
Myocardial infarction. Male mice on a CD1 background, ranging in age from 7-12 weeks, underwent coronary artery ligation to produce myocardial infarction. Mice were anaesthetized by intraperitoneal injection of 1.25% Avertin (2,2,2-tribromoethanol, 20 μl g -1 body weight) and intubated with a 20-gauge intravenous catheter. Animals were ventilated with a volume-controlled respirator (Harvard Apparatus) with 200 μl per cycle at a respiratory rate of 110 cycles min -1 . After thoracotomy, the left coronary artery was ligated with an 8-0 nylon suture 1-2 mm below the tip of the left auricle. Occlusion was confirmed by the change of colour (pallor) of the anterior wall of the left ventricle. The chest cavity and skin were closed with 5-0 silk sutures. The animals were extubated and allowed to recover from surgery on a warm plate for 1 h. Sham-operated mice underwent the same procedure without tying the suture, but passing it below the coronary artery.
Histology and in situ hybridization. Haematoxylin and eosin (H&E) staining, sirius red staining, detection of β-galactosidase activity and in situ hybridization analysis were performed as detailed in the Supplementary Information.
Hydroxyproline assay. Hydroxyproline content of heart tissues was measured as described previously 34, 35 , with some modifications. The left ventricle was freshly collected from each heart and vacuum-dried. Each vacuum-dried tissue was weighed, minced and hydrolysed in vacuum-sealed 6 M HCl (1 ml) at 116 °C overnight. Hydrolysed samples were dried in a speed-vac overnight. The dried pellet was dissolved in water, re-dried in a speed-vac overnight, re-dissolved in water and centrifuged for 5 min. To each supernatant, phenolphthalein (40 μl) was added as a pH indicator and KOH solution was added until the colour of the solution became pale pink. Neutralized samples were centrifuged for 5 min and the supernatant used for the hydroxyproline measurement. To each diluted (typically 20-fold) sample (2 ml), 1 ml of 0.05 M chloramine-T (0.285 g 5 ml -1 dH 2 O, 7.5 ml methyl cellosolve, 12.5 ml Na-citrate/Na-acetate buffer) was added and incubated for 20 min at room temperature. Chloramine-T was then destroyed with 1 ml 3.15 M perchloric acid (7.56 ml 60% perchloric acid, 16.44 ml dH 2 O). After 5 min at room temperature, 1 ml of 20% p-dimethylaminobenzaldehyde solution (dissolved in methyl cellosolve) was added and each sample was vortexed and incubated for 20 min at 60 °C. Hydroxyproline content was determined by measuring the absorbance of each sample at 557 nm. A standard curve was generated using hydroxyproline solutions (0, 2, 4, 6, 8, 10 μg 2 ml -1 ).
Echocardiography. Echocardiography was performed on wild-type and Sfrp2-null infarcted and sham-operated mice at days 1, 7 and 14 using a VisualSonic Vevo 770 ultrasound imager equipped with a 40 MHz RSV-704 scan head. In each instance, mice were anaesthetized with 1% isoflurane and parasternal short-axis and long-axis B-mode and M-mode views were recorded. The shortaxis view was used to measure anteroposterior internal diameter, anterior wall thickness and posterior wall thickness at end-diastole and end-systole at the mid-papillary level. The long-axis view was used to monitor outflow through the aortic root by pulsed Doppler to measure peak velocity of blood through the aortic valve. Left ventricular systolic function was assessed by ejection fraction: %EF =[(EDv -ESv)/EDv ] × 100. The observer was unaware of the genotypes and treatment. would have expressed sFRP2 (blue-staining) was observed in the infarcted sFRP2-null heart. The apparent increase of blue-staining in the sFRP2-deficient section is due to the insertion of two copies of the β-galactosidase gene in null mice as opposed to one copy in heterozygotes. Scale bars are shown in each panel.
Figure S6
Full scans of autofluorograms and immunoblots. Full scans are shown of Fig. 1a-f, Fig. 2a&c, Fig. 3a -d&f, and Fig. 4a&b. Figs. 1e, 1f , 2c, and 3f in the paper each combined two different exposures of the same blot to best demonstrate salient features described in the text. Full scans of both exposures are shown here.
Supplementary Information.
METHODS:
Biochemical and cell biology methods.
To create FLAG-tagged BMP1 lacking only protease domain sequences, a previously described construct comprising FLAG-tagged full-length human BMP1 sequences in pCDNA4/TO 1 was digested with XcmI and PflmI, blunt-ended with T4 DNA polymerase, and re-ligated.
To create a construct for expression of Xenopus Szl, cDNA was synthesized from The two overlapped PCR products were then used as templates to generate full length Szl D92N by PCR using Szl5' and Szl3' as outside primers. All constructs were verified by DNA sequencing on both strands. Recombinant proteins were expressed in 293 EBNA-1 cells, transfected using LiprofectAMINE (Gibco), and selected in media containing 100 µg/ml Zeocin and 10 µg/ml BLASTICIDIN. All the other primers are as previously described 3 .
